PotassiumNEW2026-09

Resistant Hypertension Variants Link to Hyperaldosteronism and Potassium Levels.

Tragante Vinicius, Sulem Patrick, Thorleifsson Gudmar, Frigge Michael L et al. — Hypertension (Dallas, Tex. : 1979)

Summary

This study explored genetic factors that might explain why some people have high blood pressure that's hard to control, known as resistant hypertension. Researchers found specific genetic variations linked to lower potassium levels and a condition called hyperaldosteronism, where the body produces too much aldosterone. These findings suggest that these genetic links could play a significant role in why resistant hypertension develops.

AI-generated summary — read the original

Key points

Resistant hypertension is high blood pressure that doesn't respond well to standard medications.
Genetic factors linked to lower potassium levels and higher aldosterone may contribute to resistant hypertension.
People with resistant hypertension often have lower potassium even before starting medication.
Understanding these genetic links could lead to more targeted treatments for resistant hypertension.

What the study looked at

What question did the study ask? This research aimed to understand the underlying genetic reasons why some individuals develop resistant hypertension, a form of high blood pressure that is difficult to control with standard medications. How was it studied? Scientists conducted a large-scale genetic study, called a genome-wide association study, involving over 47,000 participants from Iceland, the UK, and the US. They compared the genetic profiles of people with resistant hypertension to those whose high blood pressure was well-controlled by medication. What did it find? The study identified several genetic variations linked to resistant hypertension. Notably, many of these variations were associated with lower potassium levels in the blood and an increased risk of hyperaldosteronism, a condition where the body produces too much of the hormone aldosterone. The findings suggest that genetically influenced hyperaldosteronism might be a major contributor to resistant hypertension. Interestingly, individuals with resistant hypertension often had lower potassium levels even before starting any blood pressure medication.

Dietary takeaway

While this study highlights a genetic link, maintaining adequate potassium intake through diet remains important for overall cardiovascular health. Foods rich in potassium, such as fruits, vegetables, and legumes, can help support healthy blood pressure. However, it's crucial to remember that this is one study, and dietary changes, especially for resistant hypertension, should always be discussed with a healthcare professional.

Abstract

BACKGROUND: We aimed to characterize the genetic architecture of resistant hypertension (rHTN), which affects up to 18% of hypertensive individuals and increases cardiovascular disease risk. METHODS: We conducted a genome-wide association study on rHTN, defined as use of 3 or more concomitant antihypertensive drugs for at least 6 months without reaching blood pressure target (in the 3-drug case), comparing it to controlled hypertension (cHTN), in which persons on 1 or 2 antihypertensives for at least 6 months reach target BP after 30 days of therapy initiation. The study included 23 508 rHTN cases and 24 393 cHTN controls, identified through drug prescription and blood pressure data from Iceland (deCODE), the UK (UK Biobank), and the US (eMERGE). Further analyses included comparisons with all hypertensive individuals (diagnosed with code I10) and normotensives (no hypertension diagnosis). RESULTS: We found 24 rHTN variants, 17 of which used published BP variants as prior. Fifteen risk-increasing rHTN alleles are associated with lower serum potassium and increased hyperaldosteronism risk. Individuals with rHTN and cHTN had lower potassium levels before drug therapy than normotensives. All antihypertensive drug classes increased potassium levels in cHTN, while only aldosterone antagonists increased levels in rHTN. Mendelian randomization analysis was consistent with rHTN being a manifestation of hyperaldosteronism. The variant conferring the largest effect on both rHTN and hyperaldosteronism is a stop-gain variant in in the aldosterone pathway. CONCLUSIONS: We discovered sequence variants that have different effects on rHTN and cHTN. Our study indicates that genetically determined hyperaldosteronism may be largely accountable for rHTN.

View on PubMed →DOI: 10.1161/HYPERTENSIONAHA.123.22301